Binimetinib
Patients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical CenterSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Patients With BRAFV600 E or BRAFV600K Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Encorafenib University of Heidelberg Medical Center | Phase 2 | B |
Same molecule, other indications
Binimetinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →